This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Thursday's Health Winners & Losers

Angiotech Pharmaceuticals (ANPI) saw its shares edge lower after the company's profit met analysts' estimates in the latest quarter. The company earned $1.8 million, or 2 cents a share, for the second quarter. Excluding litigation expenses, the company earned 20 cents a share, in line with estimates. Shares of Angiotech lost 2 cents to $11.85.

Shares of pain drug developer Pozen (POZN) sank following the company's announcement that its second-quarter losses doubled.

Pozen lost $8.4 million, or 29 cents a share, in the quarter compared with a loss of $4.1 million, or 14 cents a share, last year. The company attributed the wider loss to an extension of the amortization period for recognizing upfront payments for its drug Trexima. Analysts surveyed by Thomson First Call were expecting a loss of 26 cents a share. Total revenue reached $97.7 million, while analysts were expecting $89.9 million. Shares added 1 cent to $10.45.

Drug developer CoTherix (CTRX) was down 10% to $7.41 a day after its latest quarterly report.

The company reported sales of $16.2 million, up 12% from the first quarter. However, its loss was $10.9 million, or 38 cents a share, compared with a loss of $6.3 million, or 26 cents a share, last year.

Among other movers were Targeted Genetics (TGEN), down 10.7% to $2, and Bioenvision (BIVN), off 2.4% to $4.50. Titan Pharmaceuticals (TTP) was up 13.5% to $2.10, Cell Therapeutics (CTIC) rose 2.4% to $1.29, Adventrx Pharmaceuticals (ANX) gained 8% to $3.26, and BioMarin (BMRN) was up 7.8% to $15.54.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,195.42 +221.11 1.30%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,566.1380 +16.9120 0.37%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs